Department of Health Evidence and Policy, Mount Sinai School of Medicine, New York, NY, USA.
J Vasc Surg. 2011 Jul;54(1):1-12.e6; discussion 11-2. doi: 10.1016/j.jvs.2010.12.049. Epub 2011 Apr 17.
OBJECTIVES: Historically, women have higher procedurally related mortality rates than men for abdominal aortic aneurysm (AAA) repair. Although endovascular aneurysm repair (EVAR) has improved these rates for men and women, effects of gender on long-term survival with different types of AAA repair, such as EVAR vs open aneurysm repair (OAR), need further investigation. To address this issue, we analyzed survival in matched cohorts who received EVAR or OAR for both elective (eAAA) and ruptured AAA (rAAA). METHODS: Using the Medicare Beneficiary Database (1995-2006), we compiled a cohort of patients who underwent OAR or EVAR for eAAA (n = 322,892) or rAAA (n = 48,865). Men and women were matched by propensity scores, accounting for baseline demographics, comorbid conditions, treating institution, and surgeon experience. Frailty models were used to compare long-term survival of the matched groups. RESULTS: Perioperative mortality for eAAAs was significantly lower among EVAR vs OAR recipients for both men (1.84% vs 4.80%) and women (3.19% vs 6.37%, P < .0001). One difference, however, was that the survival benefit of EVAR was sustained for the 6 years of follow-up in women but disappeared in 2 years in men. Similarly, the survival benefit of men vs women after elective EVAR disappeared after 1.5 to 2 years. For rAAAs, 30-day mortality was significantly lower for EVAR recipients compared with OAR recipients, for both men (33.43% vs 43.70% P < .0001) and women (41.01% vs 48.28%, P = .0201). Six-year survival was significantly higher for men who received EVAR vs those who received OAR (P = .001). However, the survival benefit for women who received EVAR compared with OAR disappeared in 6 months. Survival was also substantially higher for men than women after emergent EVAR (P = .0007). CONCLUSIONS: Gender disparity is evident from long-term outcomes after AAA repair. In the case for rAAA, where the long-term outcome for women was significantly worse than for men, the less invasive EVAR treatment did not appear to benefit women to the same extent that it did for men. Although the long-term outcome after open repair for elective AAA was also worse for women, EVAR benefit for women was sustained longer than for men. These associations require further study to isolate specific risk factors that would be potential targets for improving AAA management.
目的:既往研究表明,女性在接受腹主动脉瘤(AAA)修复治疗时,程序性相关死亡率高于男性。虽然血管内动脉瘤修复术(EVAR)改善了男性和女性的相关比率,但不同类型的 AAA 修复(如 EVAR 与开放动脉瘤修复术(OAR))对长期生存的影响仍需进一步研究。为解决这一问题,我们分析了接受 EVAR 或 OAR 治疗择期 AAA(eAAA)和破裂性 AAA(rAAA)的匹配队列的生存情况。
方法:我们使用 Medicare 受益人大数据库(1995-2006 年),收集了一组接受 OAR 或 EVAR 治疗的 eAAA(n=322892)和 rAAA(n=48865)患者。采用倾向评分匹配男性和女性,以基线人口统计学、合并症、治疗机构和外科医生经验为基础。使用脆弱性模型比较匹配组的长期生存情况。
结果:对于 eAAA,EVAR 治疗患者的围手术期死亡率显著低于 OAR 治疗患者,男性为 1.84% vs. 4.80%(P<0.0001),女性为 3.19% vs. 6.37%(P<0.0001)。然而,一个不同点是,女性 EVAR 治疗后的生存获益可维持 6 年随访期,而男性则在 2 年内消失。同样,男性接受择期 EVAR 治疗后的生存获益在 1.5 至 2 年内消失。对于 rAAA,EVAR 治疗患者的 30 天死亡率显著低于 OAR 治疗患者,男性为 33.43% vs. 43.70%(P<0.0001),女性为 41.01% vs. 48.28%(P=0.0201)。男性接受 EVAR 治疗的 6 年生存率显著高于接受 OAR 治疗的患者(P=0.001)。然而,女性接受 EVAR 治疗后的生存获益在 6 个月内消失。女性接受紧急 EVAR 治疗后的生存率也显著高于男性(P=0.0007)。
结论:AAA 修复后长期结局存在明显的性别差异。对于 rAAA,女性的长期结局明显差于男性,而微创 EVAR 治疗似乎并没有像男性那样使女性受益。尽管女性接受择期 OAR 治疗的长期结局也较差,但 EVAR 治疗对女性的获益持续时间长于男性。这些关联需要进一步研究,以确定可能改善 AAA 管理的特定风险因素。
J Vasc Surg. 2012-2-8
J Vasc Surg. 2010-1-15
JAMA Surg. 2025-1-1
Wideochir Inne Tech Maloinwazyjne. 2024-3
Front Endocrinol (Lausanne). 2021
Kardiochir Torakochirurgia Pol. 2021-3
World J Surg. 2020-6